The Insider: Meet the CEOs Webcast Replay
We were joined by a CEO of an exciting ASX-listed business, who gave valuable insight to their industries and companies future prospects.
- (ASX: DXB) Dimerix Limited – Dr Nina Webster
Recorded on 23rd November 2022 at 12pm (AEDT).
FEATURED SPEAKERS
Dr Nina Webster
CEO and MD - Dimerix Limited (ASX: DXB)
Dimerix is a clinical-stage biopharmaceutical company with multiple Phase 3 opportunities, and considered by fund manager Andrew Chapman as one of the cheapest stocks in its sector. The company owns a scalable, proprietary technology (Receptor-HIT) that is available for licensing globally and used in the drug development process to rapidly screen and identify new drug opportunities. Receptor-HIT was used to develop Dimerix’s DMX-200, a Phase 3 clinical drug developed to treat diabetic kidney disease and COVID-induced pneumonia and respiratory complications. DMX-200 has been granted patents in key territories, including Canada, China and Japan, and as at September 2022 holds ‘orphan drug’ exclusivity in the US and Europe for 7-10 years.
